Bertolini Jeffrey sold $11K of CARL

Bertolini Jeffrey (Chief Operating Officer) sold 747 shares of CARLSMED, INC. (CARL) at $15.15 on 2026-11-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bertolini Jeffrey
Published Nov 4, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CARL
Neutral
high confidence
Mentioned
$CARL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CARLNeutralLow
01

Why it matters

The disclosed sale is unlikely to move the stock significantly but may be noted by short-term traders.

02

Market read

Minor insider sale with limited market impact.

03

What to watch

The insider holds a sizable position; the sale represents less than 0.5% of holdings.

Relevance 2/10Novelty 2/10Timing: today

Background

SEC Form 4 filings provide transparent disclosure of insider transactions. Small sales via 10b5-1 plans are common and often pre-scheduled.

Company-level read

Ticker impact

$CARLNeutralHigh confidence
Context

Form 4 shows COO sold 747 shares for $11.3K via 10b5-1 plan, reducing holdings to 22,489 shares.

Expected impact

possible modest downward pressure as market prices in the sale

Evidence & confidence

The transaction is small relative to float and disclosed via a 10b5-1 plan, limiting immediate impact.

Market effects

None

None

None

Counterpoint

The sale may be routine and not indicative of insider concern.

Key entities

  • Bertolini Jeffrey

    Chief Operating Officer of Carlsmed, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CARLHigh

Carlsmed (CARL) Q3 2026 Earnings Call Transcript

Carlsmed (CARL) reported 65% revenue growth in Q3 2026, raising full-year guidance to $78M-$80M. The company launched new products and expects 2027 catalysts. Management updates include new COO, CFO, and Chief Product & AI Officer. Clinical data shows reduced reoperation rates, and new reimbursement codes may boost hospital adoption.

$CARLMed

Carlsmed Q3 Earnings Call Highlights

Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.

$CARLHigh

Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (